COMy 2022 | The impact of daratumumab on the myeloma treatment landscape
Claudio Cerchione
• 13 May 2022
In this video, Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the efficacy of daratumumab and its impact on the myeloma treatment landscape. Dr Cerchione highlights the benefits of daratumumab in the frontline setting, as well as its use for both transplant-eligible and ineligible patients. Dr Cerchione also comments on the improved responses observed in high-risk patients after receiving daratumumab, and further discusses combination approaches that are showing great promise. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
